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The 4th World Symposium on Pulmonary Hypertension was the first international meeting to focus not only on
pulmonary arterial hypertension (PAH) but also on the so-called non-PAH forms of pulmonary hypertension (PH).
The term “non-PAH PH” summarizes those forms of PH that are found in groups 2 to 5 of the current classifica-
tion of PH, that is, those forms associated with left heart disease, chronic lung disease, recurrent venous throm-
boembolism, and other diseases. Many of these forms of PH are much more common than PAH, but all of them
have been less well studied, especially in terms of medical therapy. The working group on non-PAH PH focused
mainly on 4 conditions: chronic obstructive lung disease, interstitial lung disease, chronic thromboembolic PH,
and left heart disease. The medical literature regarding the role of PH in these diseases was reviewed, and rec-
ommendations regarding diagnosis and treatment of PH in these conditions are provided. Given the lack of ro-
bust clinical trials addressing PH in any of these conditions, it is important to conduct further studies to establish
the role of medical therapy in non-PAH PH. (J Am Coll Cardiol 2009;54:S85–96) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.008o
d
b
fi
P
a
m
e
f
s
s
d
p
p
o
o
E
a
T
urevious international meetings on pulmonary hyperten-
ion (PH) have focused predominantly on pulmonary
rterial hypertension (PAH), a form of PH that is usually
evere but overall quite rare. The 4th World Symposium
as the first to assign a working group to address in detail
he so-called non-PAH forms of PH, that is, those forms
f PH that are encountered in patients with chronic
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isease (ILD), left heart disease (LHD), venous throm-
oembolism, and other conditions. It is a paradox in the
eld of PH that one of the less common forms, that is,
AH, has been extensively studied, whereas fewer data
re available on other types of PH, many of which are far
ore common. At the same time, drugs with proven
fficacy in PAH (1–3) are being increasingly used in other
orms of PH, despite the virtual absence of clinical trials
upporting this approach.
Pulmonary hypertension in chronic lung disease sub-
umes COPD, ILD, and other diffuse parenchymal lung
iseases such as sarcoidosis, connective tissue disease, or
ulmonary Langerhans cell histiocytosis. Space limitation
revents a discussion of the rarer diseases, such as sarcoid-
sis and pulmonary Langerhans cell histiocytosis, which are
ften associated with clinically relevant PH (4).
pidemiology, Features,
nd Importance of PH in COPD
he prevalence of PH in COPD depends on the population
nder study, the definitions applied, and the tools used to
valuate patients (5). Most hemodynamic studies have been
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vanced disease. Three recent stud-
ies have provided data in large
series of patients, the majority of
them in the Global initiative for
chronic Obstructive Lung Disease
(GOLD) IV stage. In 1 study
among 120 patients with severe
emphysema (mean forced expira-
tory volume in 1 s [FEV1], 27%
predicted) undergoing evaluation
for lung volume reduction sur-
gery (6), the incidence of PH,
defined as a mean pulmonary
artery pressure (mPAP)20 mm
Hg, was 91%, although in the
majority of patients (86%), it was
in the mild-to-moderate range
(mPAP 20 to 35 mm Hg). Only
5% of the patients showed an
mPAP 35 mm Hg. The cor-
relation between mPAP and
lung function was weak (FEV1,
r2  0.11 and PaO2, r
2  0.03).
The mPAP was more closely
related to pulmonary capillary
wedge pressure (PCWP) (r2 
0.32), which was mildly elevated
in the majority of patients, sug-
gesting the presence of diastolic
left ventricular (LV) dysfunction
in advanced COPD. However,
gas trapping with elevated in-
trathoracic pressures may be an
alternative explanation for the
increased PCWP.
In a retrospective analysis of
pulmonary hemodynamic studies
in 998 COPD patients (7), 27
patients had severe PH, defined
as an mPAP 40 mm Hg. Of
the 27, 16 had alternative expla-
nations for PH. Among the re-
maining 11 (1.1% of the whole
group), COPD was the only
identifiable cause of PH. This
subset of patients had only
moderate airway obstruction
FEV1 50% predicted), but at the same time, they showed
evere hypoxemia, hyperventilation, and a very low dif-
usion capacity of the lung for carbon monoxide
DLCO). The survival time of these patients was much
horter than in the other patients. These findings indicate
hat there is a subset of COPD patients with “out of
roportion” PH sharing some clinical features with idio-
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
COPD  chronic
obstructive pulmonary
disease
CT  computed
tomography
CTEPH  chronic
thromboembolic pulmonary
hypertension
DLCO  diffusion capacity
of the lung for carbon
monoxide
ERA  endothelin receptor
antagonist
FEV1  mean forced
expiratory volume in 1 s
ILD  interstitial lung
disease
IPF  idiopathic pulmonary
fibrosis
LHD  left heart disease
LV  left ventricular
mPAP  mean pulmonary
artery pressure
PAH  pulmonary arterial
hypertension
PCWP  pulmonary
capillary wedge pressure
PDE-5 
phosphodiesterase-5
PEA  pulmonary
endarterectomy
PH  pulmonary
hypertension
PVR  pulmonary vascular
resistance
RCT  randomized
controlled trial
RHC  right heart
catheterization
RV  right ventricular
SPAP  systolic pulmonary
arterial pressure
TR  tricuspid
regurgitationathic PAH. hIn a study of 215 patients with severe COPD (FEV1 24%
redicted) who were candidates for lung volume reduction
urgery or lung transplantation, PH, defined as an mPAP
25 mm Hg, was present in 50%, although it was mostly
ild (mPAP 26 to 35 mm Hg) (8). In 9.8% of these
atients, PH was considered moderate (mPAP 36 to 45 mm
g), and in 3.7%, severe (mPAP 45 mm Hg). Cluster
nalysis identified a subset of patients with moderate im-
airment of airway function, high PAP, and severe arterial
ypoxemia, further supporting the concept of the existence
f a subgroup of COPD patients with moderate airflow
bstruction and “out of proportion” PH.
The overall burden of PH in patients with COPD is
ubstantial. If 1% of patients with advanced COPD have
evere PH with mPAP40 mm Hg (7), extrapolation from
he U.S. or French prevalence figures on COPD suggests a
revalence of severe PH in COPD patients of 3 to 17 per
illion, similar to the prevalence of PAH (9). However,
ith an mPAP cutoff of 35 mm Hg rather than 40 mm Hg,
he prevalence of out-of-proportion PH in advanced
OPD increases by a factor of approximately 5 to 10. When
ll patients with mPAP 20 mm Hg are taken into
ccount, the population-based prevalence of PH in COPD
ould be in the range of 100 to 150 per million.
The hemodynamic features of PH in COPD differ from
hose seen in PAH. In general, the degree of PH is low to
oderate in magnitude, with mPAP rarely exceeding 35 to
0 mm Hg. Both right atrial pressure and PCWP tend to be
ormal or mildly elevated (10–13). The rate of progression
f PH in COPD is slow, with an annual increase in mPAP
f 0.4 to 0.7 mm Hg per year (14,15). Patients with COPD
ften develop right ventricular (RV) diastolic dysfunction
ith elevated RV filling pressures resulting in fluid retention
nd edema, especially during COPD exacerbations. Cardiac
utput in COPD is usually preserved and may increase
uring exacerbation episodes. Right ventricular forward
ailure, that is, low cardiac output as commonly seen in
nd-stage PAH, is exceedingly rare in COPD-associated
H, and death from right heart failure is a rarity in this
roup of patients.
Numerous studies have shown that the presence of even
ild PH is of prognostic relevance in patients with COPD.
longitudinal 7-year study of 50 patients with COPD
howed that survival was inversely related to pulmonary
ascular resistance (PVR) (13). In a 15-year follow-up study
ith 200 patients (16), the presence or absence of PH was
ne of the strongest predictors of mortality. In a 1981 study
f 175 patients with COPD (10), those with mPAP 20
m Hg had shorter survival time than those in whom PAP
as normal. A more recent study involving 84 patients
eceiving long-term oxygen therapy observed that mPAP
as the best predictor of mortality (17). The 5-year survival
ate was 36% in patients with mPAP 25 mm Hg, whereas
n patients with mPAP 25 mm Hg the survival rate was
2%. In this study neither the FEV1 nor the degree of
ypoxemia or hypercapnia had prognostic value.
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June 30, 2009:S85–96 Diagnosis, Assessment, and Treatment of Non-PAH PHpidemiology, Features,
nd Importance of PH in ILD
he term “ILD” summarizes a heterogeneous group of lung
iseases with similar clinical, radiographic, and physiologic
anifestations. The prevalence of PH in patients with ILD
aries greatly as a function of the underlying disease and the
iagnostic mode used to identify PH. The most extensive
ata have been published in idiopathic pulmonary fibrosis
IPF).
The incidence and prevalence of PAH in IPF remain
nclear, with widely varying estimates. The differences
eflect varying patient populations, varying underlying dis-
ase severity, and differing diagnostic modalities. In general,
tudies of patients undergoing assessment for lung trans-
lantation have suggested a higher prevalence of PH. In one
arly study of ventricular dysfunction and tricuspid regurgi-
ation (TR) in patients evaluated for lung transplantation,
0 of 77 IPF patients had echocardiographic evidence of RV
ysfunction (18). Another study retrospectively identified
n estimated systolic pulmonary arterial pressure (SPAP)
35 mm Hg in 84% of 88 patients and50 mm Hg in 16%
19). The combination of emphysema in the upper lung
ones and pulmonary fibrosis in the lower lobes on high-
esolution computed tomography (CT) of the chest seems
o be associated with a higher prevalence of PH (20,21).
chocardiographic data are difficult to interpret because the
perating characteristics of echocardiography to estimate
PAP in patients with advanced lung disease seem to be
uite poor (22).
Recent studies have used right heart catheterization
RHC) to accurately measure pulmonary pressures in IPF
atients. Two retrospective analyses of IPF patients
ndergoing RHC reported PH (defined as mPAP 25
m Hg) in 31.6% (23) and 33.9% (24) of the patients,
espectively. In the United Network for Organ Sharing
nd the Organ Procurement and Transplant Network
egistries for IPF patients listed for lung transplantation
etween January 1995 and June 2004 (25), 2,525 of the
,457 patients listed had RHC results available. Of these,
32 (37.0%) had an mPAP 25 mm Hg, whereas 231
9.1%) had an mPAP 40 mm Hg. Among 70 IPF
atients evaluated prospectively (26), PH (resting mPAP
25 mm Hg) was detected in only 6 patients (8.1%) at
aseline.
Several groups have emphasized the prognostic impor-
ance of PAH complicating IPF. Echocardiographically
efined PH (SPAP 50 mm Hg) has been associated with
mpaired survival (19). Echocardiographically defined PH
n IPF patients with superimposed emphysema negatively
nfluences survival (20). In IPF patients undergoing
HC before listing for lung transplantation, the presence
f PAH correlated linearly with mortality (23). In a
rospective study, an mPAP 17 mm Hg was predictive
f mortality (26). issessment of PH in Chronic Lung Disease
yspnea and fatigue are symptoms of chronic lung disease
s well as PH. Thus, patients with chronic lung diseases
hould be evaluated for PH when the symptoms are more
evere than one would expect from lung function data, or
hen signs of right heart failure develop. Suspicion of PH
hould be high if clinical deterioration is not matched by a
ecline in pulmonary function. Profound hypoxemia, hy-
erventilation, and a low DLCO are indicators of PH.
Once PH is suspected, patients should be evaluated by
oppler echocardiography. A measurable TR velocity,
owever, is less likely to be observed in patients with
OPD than in patients with PAH, ranging between 24%
nd 77% (27–29). Even if a TR jet is available, echocar-
iographic estimates of the PA pressure are often inac-
urate, and both false-positive and -negative results have
een reported. In 2 large series comparing echocardio-
raphic data and findings from RHC in patients with
hronic lung disease, the positive predictive values of
chocardiography were 32% and 68%, respectively, and
he negative predictive values were 93% and 67%, respec-
ively (22,30). The results are somewhat better but still
uboptimal in patients with ILD (22).
Plasma levels of brain natriuretic peptide (BNP) or
-terminal pro-brain natriuretic peptide (NT-proBNP)
ave also been evaluated as predictors of PH in patients with
ung disease (31,32), but these biomarkers lack sensitivity,
specially for milder forms of PH, and specificity, because
levated levels may also reflect LHD.
Given the limitations of echocardiography and biomark-
rs, RHC remains the standard for the diagnosis of PH.
his is of particular relevance for patients who also suffer
rom some degree of LV dysfunction, which seems to be a
ommon comorbidity and may contribute to the clinical
eatures of cor pulmonale.
reatment of PH in Patients
ith Chronic Lung Disease
t is self-evident that the underlying lung disease should be
ptimally treated according to relevant guidelines (33,34).
ummarizing these recommendations is beyond the scope
f this article. We will focus exclusively on the use of
H-targeted medication in patients with lung disease. So
ar, no large randomized controlled trials (RCTs) address-
ng the long-term effects of drugs targeting PH have been
erformed in patients with chronic lung disease. Patients
ith advanced lung disease, that is, those with total lung
apacities 70% predicted and FEV1/forced vital capacity
atios 50% to 60% have been excluded from RCTs in the
eld of PAH. There is not sufficient evidence showing that
rugs approved for the treatment of PAH, that is, endo-
helin receptor antagonists (ERAs), phosphodiesterase-5
PDE-5) inhibitors, and prostanoids, are safe and effective
n patients with chronic lung disease–associated PH. This is
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Diagnosis, Assessment, and Treatment of Non-PAH PH June 30, 2009:S85–96rue for patients with advanced chronic lung disease and
ild PH as well as for patients with severe PH in the setting
f chronic lung disease, independent of its severity.
Any pulmonary vasodilator has the potential to worsen
as exchange in patients with chronic lung disease, and the
ffects of these drugs may vary substantially depending on
hether the underlying disease has obstructive or restrictive
eatures (35). Short-term studies have been performed in
LD patients with sildenafil (36), bosentan (37), and in-
aled iloprost (38), and these drugs had no adverse effects
n oxygenation. In contrast, unpublished data suggest that
ildenafil may worsen oxygenation in patients with COPD
nd PH (39), and it has been shown that sildenafil can
nhibit hypoxic pulmonary vasoconstriction (40). In another
tudy in COPD patients, sildenafil did not improve stroke
olume at rest or during exercise (41). A small RCT with
osentan in patients with COPD and mild PH found a
ignificant deterioration of the PaO2. At the same time,
here was no improvement in exercise capacity, peak oxygen
ptake, and health-related quality of life (42). All in all,
uch more evidence is needed before the use of PH-
argeted drugs can be recommended for certain subpopula-
ions of patients with chronic lung disease.
orking Group Recommendations for PH in
hronic Lung Disease (COPD, ILD, and Other Forms)
iagnosis and assessment of PH in chronic lung disease
In patients with chronic lung disease, the presence of PH
should be suspected when the symptoms are more severe
than expected based on lung function data, or when signs
of right heart dysfunction are present. Profound hypox-
emia, hyperventilation, or low DLCO values can be
indicators of PH (E/A). (Please refer to Barst et al. [43]
for an explanation of the evidence-based grading system.)
Doppler echocardiography remains the most useful non-
invasive tool for assessing the presence of PH in patients
with chronic lung disease, but both false-positive and
false-negative results are not uncommon (E/B).
Biomarkers such as BNP or NT-proBNP need to be
further evaluated. They seem to be useful screening
tools for the presence of PH in patients with chronic
lung disease, although they lack sensitivity and speci-
ficity (E/B).
If the presence of PH is going to affect the management
of a patient with chronic lung disease, confirmation by
RHC is recommended (E/A).
Patients with chronic lung disease and severe PH (i.e.,
mPAP 35 mm Hg and/or signs of right heart failure)
should be referred to a center with expertise in PH (E/A).
The use of RHC is strongly recommended in clinical
trials studying patients with chronic lung disease and PH
to categorize the patients under study and to identify
subpopulations likely to benefit from PH-targeted drug
therapy (E/A). areatment of PH in chronic lung disease
The underlying lung disease should be optimally treated
according to the respective guidelines, including the use
of long-term oxygen therapy in patients with chronic
hypoxemia (E/A).
There is no sufficient evidence that the drugs currently
used for PAH are safe and effective in patients with PH
associated with chronic lung disease (E/A).
Patients with PH and chronic lung disease should be
treated in the setting of clinical trials whenever possi-
ble (E/A).
PH in various lung diseases should be studied separately,
because patients with COPD and PH may respond
differently to medical therapy than patients with ILD and
PH (E/A).
Registries are needed to obtain data from patients with
very rare conditions (E/A).
The use of drugs currently approved for PAH in patients
with chronic lung disease is not recommended until
further data are available (E/B).
linical trial strategy for PH in chronic lung disease. It
s unlikely that patients with end-stage lung disease are
oing to derive a substantial benefit from PH treatment. In
ontrast, patients with mild-to-moderate chronic lung dis-
ase but severe PH may be good candidates for clinical trials
ith drugs targeting the pulmonary vascular component.
ecause one would not expect all subpopulations of patients
ith chronic lung disease to respond similarly to PH
edications, it is crucial that the patients under study be
arefully evaluated and characterized: this will include the
se of RHC to define the severity of PH and the hemody-
amic profile.
A 2-step approach is recommended to evaluate drugs
argeting PH in the setting of chronic lung disease.
Step 1. Safety, proof-of-concept, and preliminary effi-
cacy: important safety parameters include vital signs and
blood gases (both PaO2 and PaCO2). Preliminary efficacy
can be assessed by hemodynamics, exercise capacity (i.e.,
6-min walk test), peak oxygen uptake, and ventilator
efficacy measured during cardiopulmonary exercise test-
ing, and improvement of oxygenation at rest and during
exercise (E/A).
Step 2. Long-term safety and efficacy: prevention of clinical
worsening (i.e., morbidity and mortality), improvements in
exercise capacity and quality of life (E/A).
hronic thromboembolic pulmonary hypertension
CTEPH). CTEPH results from obstruction of the pul-
onary vascular bed by nonresolving thromboemboli. It has
een estimated that there are 2,500 new cases of CTEPH
ach year in the U.S. (44). In a prospective study following
urvivors of acute pulmonary embolism, 3.8% of patients
eveloped CTEPH within 2 years (45). However, up to
0% of patients with CTEPH have not had a clinically
pparent acute pulmonary embolic episode (46–48). Sple-
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June 30, 2009:S85–96 Diagnosis, Assessment, and Treatment of Non-PAH PHectomy, ventriculoatrial shunt for the treatment of hydro-
ephalus, chronic central intravenous lines, inflammatory
owel disease, and osteomyelitis seem to be risk factors for
eveloping CTEPH (49). However, the absence of such a
istory does not rule out CTEPH. Novel interesting con-
epts are derived from the observation of abnormal (lysis-
esistant) fibrinogen variants underlying clot nonresolution
n CTEPH (50).
CTEPH differs from PAH by its major vessel involve-
ent of the vascular remodeling process (51), which can be
pproached surgically by pulmonary endarterectomy (PEA);
his has evolved over 4 decades to become the treatment of
hoice (52,53). The outcomes of PEA with regard to
unctional status, quality of life, hemodynamics, and RV
unction have been very favorable, including normalization
f hemodynamics and exercise capacity in frequent cases.
owever, small vessel arteriopathy is variably present in
TEPH (54,55), and small vessel lesions are an important
eterminant of the outcome after PEA.
iagnosis of CTEPH. The recommended strategy for di-
gnosis and evaluation of CTEPH is shown in Figure 1 (55).
The perfusion lung scan is the examination of choice for
uling out CTEPH. A normal or low-probability perfusion
can in a patient with PH effectively rules out CTEPH.
atients with operable CTEPH typically have at least 1
egmental or larger perfusion defect with normal or near-
ormal ventilation (56,57). However, the complete absence
f perfusion to 1 lung should raise suspicion for other
rocesses, such as malignancy, mediastinal fibrosis, congen-
tal absence of the pulmonary artery, or vasculitis.
Contrast-enhanced chest CT findings in CTEPH in-
lude the following: chronic thromboembolic material
ithin the central pulmonary arteries, increased bronchial
rtery collateral flow, variability in the size and distribution
f pulmonary arteries, parenchymal abnormalities consistent
ith prior infarcts, and mosaic attenuation of the pulmonary
arenchyma (55). Chest CT scanning is also useful in ruling
ut significant underlying fibrotic or emphysematous dis-
ase, obstructing tumors, mediastinal fibrosis, or lymphad-
nopathy that could mimic chronic thromboembolic dis-
ase. Although a negative CT scan does not rule out the
iagnosis of CTEPH, new-generation multirow CT scan-
ers are expected to provide improved diagnostic accuracy.
Pulmonary angiography is still considered the standard
iagnostic tool in the evaluation of CTEPH. Characteristic
ngiographic findings include pouching, webs or bands with
r without post-stenotic dilation, intimal irregularities,
brupt narrowing, or total occlusion of segmental or larger
ranches (58). When performed by experienced individuals,
ngiography is safe, even in patients with severe hemody-
amic impairment (59).
Right heart catheterization for full hemodynamic assess-
ent is mandatory in the workup of CTEPH. The presence
f PH indicates a hemodynamic consequence of chronic
hromboemboli. In addition, assessment of the degree of
ight-sided heart failure by measuring right atrial pressure, sardiac output, and mixed venous O2 saturation is important
n determining severity of disease and risk from surgical
ntervention.
Other techniques with reported utility in evaluating
TEPH include pulmonary angioscopy (60), assessment of
ulmonary artery pulse pressure and reflectance (61,62), and
agnetic resonance imaging (63,64).
reatment of CTEPH. Patients with CTEPH should
eceive lifelong anticoagulation adjusted to a target interna-
ional normalized ratio between 2.0 and 3.0 to prevent
ecurrence of thromboembolic events. Figure 2 is a treat-
ent algorithm for CTEPH.
URGICAL THERAPY. The goal of PEA is to improve pulmo-
ary hemodynamics, exercise capacity, symptoms, and sur-
ival. The procedure may be curative in appropriately
elected patients. For details regarding patient selection and
he procedure itself, please refer to the paper by Keogh et al.
65) in this issue of the Journal.
EDICAL THERAPY. Although surgical intervention with
EA is the preferred treatment in appropriate candidates,
harmacotherapy may be beneficial in certain contexts: 1) in
atients with predominantly distal disease that is not sur-
ically accessible; 2) when surgery is contraindicated because
f prognostically significant comorbidity; 3) in patients who
re at high risk because of extremely poor hemodynamics
efore PEA (bridging to PEA); and 4) in patients with
ersistent or residual PH after PEA (54).
atients with inoperable disease or with persistent or
ecurrent PH after PEA. Elevation of PVR out of pro-
ortion to what is attributable to mechanical thrombus
bstruction is occasionally seen and signals a significant and
n some cases inoperable extent of peripheral vasculopathy.
igh PVR is associated with poor outcome in terms of both
urvival and persistent PH. In addition, approximately 10%
o 15% of patients show persistent or residual PH after PEA
urgery, with or without concomitant diminished functional
apacity; these individuals may benefit from adjunctive
edical treatment (66).
Several open-label studies with prostanoids, ERAs, and
DE-5 inhibitors have been performed in patients with
TEPH, and most suggest hemodynamic and clinical im-
rovement (67–70). Some open-label studies suggest improved
urvival with medical therapies compared with historical con-
rols (71,72). However, only 1 large RCT has so far been
erformed in patients with inoperable CTEPH: the BEN-
FiT (Bosentan Effects in iNopErable Forms of chronIc
hromboembolic pulmonary hypertension) study (73). This
rst randomized controlled study in inoperable CTEPH pa-
ients showed that treatment with bosentan significantly re-
uced PVR and NT-proBNP at week 16, but the 6-min walk
istance remained unchanged, and there was no treatment
ffect on time to clinical worsening. Further studies are
equired to determine whether medical therapy offers a sub-
tantial benefit in various CTEPH populations.
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Diagnosis, Assessment, and Treatment of Non-PAH PH June 30, 2009:S85–96re-PEA bridging therapy. The concept of introducing
edical treatment as a therapeutic bridge between CTEPH
iagnosis and PEA was initially proposed for continuous
ntravenous epoprostenol (74,75). A significant proportion of
TEPH patients undergoing PEA are hemodynamically
nstable in the pre-operative period, to the point where
isks from surgery in general are significantly heightened.
nder these circumstances, effective medical therapy may
mprove pre-operative hemodynamics and stability, fur-
hering post-operative stability. On the other hand, delay
n surgery may be detrimental. Thus, the use of medical
herapy and the timing of surgery should be discussed
ith the surgeon to make sure that risks are balanced.
orking Group Recommendations for CTEPH
iagnosis and assessment of CTEPH
Perfusion scintigraphy should be performed in all patients
with unexplained PH because a normal or near-normal
perfusion pattern virtually excludes CTEPH (E/A).
Patients with a history or findings suggesting CTEPH
should be evaluated at a center with expertise in this
condition. A surgeon experienced in PEA surgery should
be available at this center, or a close collaboration with
such a surgeon should exist (E/A).
Pulmonary angiography to assess operability should be
Patients with unexplained
pulmonary hypertension and a
Perfusion-
Normal
perfusion scan
CTEPH
ruled out
Further im
Multidi
Figure 1 Diagnostic Imaging Algorithm for CTEPH
*Pulmonary angiography is usually performed in conjunction with right heart catheteriz
thromboembolic pulmonary hypertension (CTEPH) and pulmonary endarterectomy. Mod
MR  magnetic resonance.performed at the center where surgery would be per-formed or at centers with an established cooperation with
a surgical center (E/A).
reatment of CTEPH
Surgical PEA is the preferred treatment of CTEPH
because it is potentially curative (E/A).
The decision of whether or not a patient is a candidate
for PEA surgery should involve a multidisciplinary team
that includes at least 1 surgeon with substantial experi-
ence in this procedure (E/A).
In severely compromised patients with surgically acces-
sible disease but for whom surgery must be delayed,
pre-operative medical therapy with prostanoids, ERAs,
or PDE-5 inhibitors may be used to improve hemody-
namics and clinical performance before surgery, but this
approach needs to be adjusted with the responsible
surgeon (E/B).
Patients with predominantly peripheral (i.e., inoperable)
disease may be candidates for medical therapy and should
be considered for enrollment in clinical trials whenever
possible (E/A).
Preliminary data suggest that drugs currently approved
for PAH may have beneficial effects in patients with
CTEPH, but as long as there are no robust data from
monary hypertension or
tory of pulmonary embolism
tigraphy
eterminate or multiple
perfusion defects
ng including CT, MR angiography,
pulmonary angiography*
wing evidence of CTEPH
inary team discussion including
 specialized surgeon
nd should be performed at centers experienced with chronic
with permission, from Hoeper et al. (54). CT  computed tomography of the chest; pul
 his
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June 30, 2009:S85–96 Diagnosis, Assessment, and Treatment of Non-PAH PHpatients with these drugs should be restricted to centers
experienced in the management of this disease (E/B).
linical trial strategy for CTEPH. There is no doubt that
rugs used in PAH, such as prostanoids or PDE-5 inhibi-
ors, improve hemodynamics in CTEPH. The question is
hether administration of these drugs also improves mean-
ngful clinical end points such as exercise capacity, quality of
ife, time to clinical worsening, and survival. At least 2
ifferent scenarios require further investigation:
Patients with operable disease but severe hemodynamic
impairment (i.e., PVR 1,000 dyne·s·cm5): these
patients have an elevated perioperative risk, and it is
unclear whether a limited period of medical treatment to
improve hemodynamics also improves outcome when
compared with immediate surgery. This problem is
extremely difficult to study because a blinded placebo-
controlled study might be considered unethical. Thus,
this question should be addressed in a carefully designed
open study involving only centers with broad experience
in the surgical and medical management of CTEPH
patients (E/B).
Patients with peripheral (inoperable) disease and those
with persistent or recurrent PH after PEA surgery are
good candidates for clinical trials. The questions that
need to be answered are whether medical therapy im-
proves exercise capacity and quality of life and whether it
Diagnosis of CTEPH wit
signs of right
Antico
Surgically accessible pulmonary
arterial obstructions
Contraindications
precluding surgery
YesNo
Perform
PEA
Clinic
medic
Persistent/recurrent symptomatic
pulmonary hypertension
Figure 2 Treatment Algorithm for CTEPH
Modified, with permission, from Hoeper et al. (54). CTEPH  chronic thromboemb
pulmonary hypertension; PEA  pulmonary endarterectomy; PVR  pulmonary vasdelays time to clinical worsening (E/A). iH Associated With LHD
HD is one of the most common causes of PH. It may
e caused by chronic heart failure attributable to LV
ysfunction of systolic or diastolic origin or by valvular
iseases, predominantly mitral valve disorders (76). Up to
0% of patients with severe LV systolic dysfunction and
p to 70% of patients with isolated LV diastolic dysfunc-
ion may develop PH, and the presence of PH is
ssociated with a poor prognosis in these patient popu-
ations (77–79).
Pulmonary hypertension with PVR 2 mm Hg/l/min
Wood units) has been reported in up to 50% of patients
eferred to transplant clinics (79). Pulmonary hyperten-
ion and RV dysfunction carry a poor prognosis for
atients with chronic heart failure (80). In one study, the
ortality rate after 28 months was 57% in patients
ith left heart failure and moderate PH, compared with
7% in patients without PH (81). Patients with a
ranspulmonary gradient 16 mm Hg have an increased
isk of post-operative RV failure after heart transplanta-
ion (82).
The pathogenesis of PH in LHD is complex. There is a
assive (pulmonary venous) component in response to in-
reased left atrial pressure (83). In some patients, a superim-
osed active component caused by pulmonary arterial vasocon-
triction and vascular remodeling may lead to a further increase
ctional limitation and/or
rt dysfunction
ation
Advanced small vessel disease
PVR disproportionately elevated
Contraindications
precluding surgery
Yes No
ls of
rapy
Consider lung
transplantation
Persistent/recurrent symptomatic
pulmonary hypertension
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n many cases, the presence of LHD is obvious, given the
atient’s history and the echocardiographic findings. Some-
imes, however, it can be extremely difficult to distinguish
etween PH caused by diastolic LV dysfunction and PAH.
isk factors of LV dysfunction are outlined in Table 1.
isk Factors Favoringagnosis of Diastolic Heart Failure
Table 1 Risk Factors FavoringDiagnosis of Diastolic Heart Failure
Clinical features
Age 65 yrs
Elevated systolic blood pressure
Elevated pulse pressure
Obesity
Hypertension
Coronary artery disease
Diabetes mellitus
Atrial fibrillation
Echocardiography
Left atrial enlargement
Concentric remodeling (relative wall thickness 0.45)
Left ventricular hypertrophy
Elevated left ventricular filling pressures (grade II to IV diastolic dysfunction)
Interim evaluation (after echocardiography)
Symptomatic response to diuretic drugs
Exaggerated increase in systolic blood pressure with exercise
Re-review of chest radiograph consistent with heart failure
Figure 3 Diagnostic Approach to Distinguish Between PAH and
See Table 1 for risk factors for diastolic heart failure. DHF  diastolic heart failure
OMT  optimized medical therapy; PAH  pulmonary arterial hypertension; PCWP
nary vascular resistance; RCT  randomized controlled trial; RHC  right heart cachocardiographic findings suggestive of diastolic LV dys-
unction include the presence of a dilated left atrium, atrial
brillation, abnormal mitral inflow pattern, and LV hypertro-
hy (84). Although echocardiography provides important in-
ormation, invasive measurements of PCWP or LV end-
iastolic pressure may be required to document the presence of
levated LV filling pressures (84). However, resting PCWP
nd LV end-diastolic pressure can be normal despite LV
iastolic dysfunction, especially when patients have been
reated with diuretics. Exercise or volume challenge has been
roposed to identify occult LV dysfunction, but these tools
ave not been fully standardized and require further evaluation.
n elevated transpulmonary gradient (mPAP–mean PCWP)
12 mm Hg is suggestive of active PH, that is, a pre-capillary
omponent of PH (84). Figure 3 depicts a suggested diagnostic
trategy to discriminate between pulmonary arteriopathy and
H related to diastolic heart failure or “heart failure with
ormal ejection fraction.”
Vasoreactivity tests using compounds with inotropic
nd/or systemic and/or pulmonary vasodilator activities
ave been recommended in heart transplant candidates to
etermine whether this procedure is feasible in patients with
HD and PH. However, there is no internationally ac-
epted standard protocol for this procedure, and the criteria
or operability or nonoperability, respectively, need to be
urther evaluated and standardized.
Caused by Diastolic Left Heart Disease
diagnosis; EF  ejection fraction; HF  heart failure; NTG  nitroglycerine;
onary capillary wedge pressure; PH  pulmonary hypertension; PVR  pulmo-
zation; WU  Wood units.PH
; Dx 
 pulm
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June 30, 2009:S85–96 Diagnosis, Assessment, and Treatment of Non-PAH PHreatment of PH associated with LHD. Optimal cor-
ection of the underlying substrate is a necessary first step
n management because treatment of LHD may decrease
H (85). Careful attention must be paid to optimize LV
lling pressures (86). In valvular heart disease such as
itral stenosis, post-operative reduction of PCWP may
ead to a rapid reduction of PAP in both passive and
ctive PH (87). However, the reduction may be incom-
lete, despite the normalization of the PCWP, in cases
ith PH caused by chronic pathological obstructive
hanges. This component may require weeks to months
o regress, even after successful valve surgery (87). In the
ajority of patients, an almost complete normalization of
H is expected.
There is an ongoing debate regarding whether drugs
sed in PAH, that is, ERAs, PDE-5 inhibitors, or
rostanoids, may be useful in patients with LHD and
H, especially when PH becomes severe and dominates
he clinical picture. Theoretical concerns about this
pproach include the possibility of causing pulmonary
dema when pulmonary vasodilators are administered to
atients with elevated LV filling pressures. This poten-
ially adverse effect, however, may be offset when the
oncomitant treatments reduce LV afterload and LV
lling pressures.
Virtually no data from long-term RCTs address the
opulation of patients with LHD and PH. Inhaled nitric
xide and prostanoids exert favorable acute hemodynamic
ffects in these patients (88 –90). However, it is of
oncern that a study of epoprostenol in heart failure
howed a higher mortality in the active treatment group
91). Large trials with ERAs in patients with LHD have
lso failed to show beneficial long-term effects, although
hese trials did not look specifically at the subset of
atients with LHD and PH (92,93). The PDE-5 inhib-
tor sildenafil improves systolic and diastolic LV function
s well as systemic vasoreactivity in experimental models
f heart failure, making it a promising agent for future
tudies in patients with LHD and PH (94,95). Results of
ecent small studies suggest that sildenafil may improve
xercise capacity and quality of life in patients with PH
aused by LHD (96 –98). However, long-term data from
arefully designed clinical studies are required before
ildenafil can be recommended for patients with LHD
nd PH because there have been instances in which drugs
sed to treat left heart failure had positive effects on
urrogate end points but decreased survival, as was the
ase with PDE-3 inhibitors (99,100).
orking Group Recommendations
or PH Associated With LHD
iagnosis and assessment of PH in LHD
Left heart disease is one of the most common causes of
PH. The presence of LHD is obvious in many
patients, but it may be occult in others, especially when hisolated LV diastolic dysfunction is present. Features
suggestive of LV diastolic dysfunction or diastolic left
heart failure include an older age, atrial fibrillation,
and an enlarged left atrium (E/A).
Right and left heart catheterization may be required to
distinguish between PAH and PH associated with
LHD (E/A).
In patients with elevated PCWP and an elevated
transpulmonary gradient, reduction of LV afterload with
nipride or other vasodilators is useful to identify an active
pulmonary arterial component of PH (E/A).
In patients with LHD and PH considered for heart
transplantation, pulmonary vasoreactivity testing with
inhaled nitric oxide or prostanoids may be used to
assess reversibility and operability, although the crite-
ria for operability or nonoperability require further
evaluation (E/A).
reatment of PH in LHD
Treatment of LHD according to established criteria is
the basis for a successful approach to patients with LHD
and PH (E/A).
Patients with end-stage heart failure and PH may be
candidates for heart transplantation (in milder, largely
reversible forms of PH) or heart–lung transplantation (if
PH is severe and fixed) (E/A).
The use of prostanoids, ERAs, and PDE-5 inhibitors
in patients with LHD and PH is not recommended
until robust data from long-term clinical trials are
available (E/A).
linical trial strategy for PH in LHD. Drugs that reduce
V afterload as well as PVR may have beneficial effects in
atients with moderate or severe PH in the setting of milder
orms of heart failure or LV diastolic dysfunction with
reserved ejection fraction. Short-term beneficial effects on
emodynamics and exercise capacity have been shown with
everal drugs, including PDE-5 inhibitors. These drugs
eed to be rigorously studied to assess long-term safety and
fficacy in patients with LHD and PH and to identify
ubpopulations of patients most likely to derive a benefit.
hese trials should address morbidity and mortality end
oints to yield meaningful results (E/A).
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